Evidence map›Paper›PMID 38790943›Full record

ReviewBiomedicines2024

Pathophysiological Link and Treatment Implication of Heart Failure and Preserved Ejection Fraction in Patients with Chronic Kidney Disease.

Giacomo Bonacchi, Valentina Alice Rossi, Manuel Garofalo, Rocco Mollace, Giuseppe Uccello, Paolo Pieragnoli, Luca Checchi, Laura Perrotta, Luca Voltolini, Giuseppe Ricciardi and 1 more

Abstract readReview
In one paragraph

Review in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Observational
  3. Observational
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Giacomo BonacchiCardiomyopathy Unit, Careggi University Hospital, 50134 Florence, Italy.ORCID 0000-0001-8305-5274
Valentina Alice RossiDepartment of Cardiology, University Hospital of Zurich, 8091 Zurich, Switzerland.ORCID 0000-0001-9235-6597
Manuel GarofaloArrhythmia and Electrophysiology Unit, Careggi University Hospital, 50134 Florence, Italy.ORCID 0009-0007-6011-0710
Rocco MollaceDepartment of Experimental Medicine, Tor Vergata University, 00133 Rome, Italy.ORCID 0000-0002-7106-5595
Giuseppe UccelloDivision of Cardiology, "A. Manzoni" Hospital-ASST Lecco, 23900 Lecco, Italy.ORCID 0000-0002-6163-8468
Paolo PieragnoliArrhythmia and Electrophysiology Unit, Careggi University Hospital, 50134 Florence, Italy.
Luca ChecchiArrhythmia and Electrophysiology Unit, Careggi University Hospital, 50134 Florence, Italy.
Laura PerrottaArrhythmia and Electrophysiology Unit, Careggi University Hospital, 50134 Florence, Italy.
Luca VoltoliniDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
Giuseppe RicciardiArrhythmia and Electrophysiology Unit, Careggi University Hospital, 50134 Florence, Italy.
Matteo BeltramiCardiomyopathy Unit, Careggi University Hospital, 50134 Florence, Italy.ORCID 0000-0001-7161-3224

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure with preserved ejection fraction (HFpEF) results from a complex interplay of age, genetic, cardiac remodeling, and concomitant comorbidities including hypertension, obesity, diabetes, and chronic kidney disease (CKD). Renal failure is an important comorbidity of HFpEF, as well as a major pathophysiological mechanism for those patients at risk of developing HFpEF. Heart failure (HF) and CKD are intertwined conditions sharing common disease pathways; the so-called "kidney tamponade", explained by an increase in intracapsular pressure caused by fluid retention, is only the latest model to explain renal injury in HF. Recognizing the different phenotypes of HFpEF remains a real challenge; the pathophysiological mechanisms of renal dysfunction may differ across the HF spectrum, as well as the prognostic role. A better understanding of the role of cardiorenal interactions in patients with HF in terms of symptom status, disease progression, and prognosis remains essential in HF management. Historically, patients with HF and CKD have been scarcely represented in clinical trial populations. Current concerns affect the practical approach to HF treatment, and, in this context, physicians are frequently hesitant to prescribe and titrate both new and old treatments. Therefore, the extensive application of HF drugs in diverse HF subtypes with numerous comorbidities and different renal dysfunction etiologies remains a controversial matter of discussion. Numerous recently introduced drugs, such as sodium-glucose-linked transporter 2 inhibitors (SGLT2i), constitute a new therapeutic option for patients with HF and CKD. Because of their protective vascular and hormonal actions, the use of these agents may be safely extended to patients with renal dysfunction in the long term. The present review delves into the phenotype of patients with HFpEF and CKD from a pathophysiological perspective, proposing a treatment approach that suggests a practical stepwise algorithm for the proper application of life-saving therapies in clinical practice.

Indexed as

angiotensin receptor blockerchronic kidney diseaseheart failure preserved ejection fractionhyperkalemianeprilysin inhibitorssodium–glucose-linked transporters 2 inhibitorstreatment

Identifiers

PMID38790943
PMCPMC11117953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.